TY - JOUR
T1 - Natural products-based antiangiogenic agents
T2 - New frontiers in cancer therapy
AU - Azevedo, Tiago
AU - Ferreira, Tiago
AU - Peña-Corona, Sheila I.
AU - Cortes, Hernán
AU - Silva-Reis, Rita
AU - da Costa, Rui M.Gil
AU - Faustino-Rocha, Ana I.
AU - Oliveira, Paula A.
AU - Calina, Daniela
AU - Cardoso, Susana M.
AU - Büsselberg, Dietrich
AU - Leyva-Gómez, Gerardo
AU - Sharifi-Rad, Javad
AU - Cho, William C.
N1 - Publisher Copyright:
© 2024 The Author(s). Food Frontiers published by Nanchang University, Northwest University, Jiangsu University, Fujian Agriculture and Forestry University, International Association of Dietetic Nutrition and Safety and John Wiley & Sons Australia, Ltd.
PY - 2024/11
Y1 - 2024/11
N2 - Angiogenesis, vital for tumor growth and metastasis, is a promising target in cancer therapy. Natural compounds offer potential as antiangiogenic agents with reduced toxicity. This review provides a comprehensive overview of natural product-based antiangiogenic therapies, focusing on molecular mechanisms and therapeutic potential. A systematic search identified relevant articles from 2019 to 2023. Various natural compounds, including polyphenols, terpenes, alkaloids, cannabinoids, omega-3 fatty acids, polysaccharides, proteins, and carotenoids, were investigated for their antiangiogenic properties. Challenges such as dose standardization, routes of administration, and potential side effects remain. Further studies, including in-depth animal models and human epidemiological studies, must elucidate clinical efficacy and safety. Synergistic effects with current antiangiogenic therapies, such as bevacizumab and tyrosine kinase inhibitors, should be explored. Additionally, the potential hormone-dependent effects of compounds like genistein highlight the need for safety evaluation. In conclusion, natural products hold promise as adjunctive therapies to conventional antineoplastic drugs in modulating angiogenesis in cancer. However, robust clinical trials are needed to validate preclinical findings and ensure safety and efficacy.
AB - Angiogenesis, vital for tumor growth and metastasis, is a promising target in cancer therapy. Natural compounds offer potential as antiangiogenic agents with reduced toxicity. This review provides a comprehensive overview of natural product-based antiangiogenic therapies, focusing on molecular mechanisms and therapeutic potential. A systematic search identified relevant articles from 2019 to 2023. Various natural compounds, including polyphenols, terpenes, alkaloids, cannabinoids, omega-3 fatty acids, polysaccharides, proteins, and carotenoids, were investigated for their antiangiogenic properties. Challenges such as dose standardization, routes of administration, and potential side effects remain. Further studies, including in-depth animal models and human epidemiological studies, must elucidate clinical efficacy and safety. Synergistic effects with current antiangiogenic therapies, such as bevacizumab and tyrosine kinase inhibitors, should be explored. Additionally, the potential hormone-dependent effects of compounds like genistein highlight the need for safety evaluation. In conclusion, natural products hold promise as adjunctive therapies to conventional antineoplastic drugs in modulating angiogenesis in cancer. However, robust clinical trials are needed to validate preclinical findings and ensure safety and efficacy.
KW - angiogenesis
KW - antiangiogenic therapy
KW - cancer treatment
KW - molecular mechanisms
KW - natural compounds
UR - https://www.scopus.com/pages/publications/85202980462
U2 - 10.1002/fft2.466
DO - 10.1002/fft2.466
M3 - Artículo
AN - SCOPUS:85202980462
SN - 2643-8429
VL - 5
SP - 2423
EP - 2466
JO - Food Frontiers
JF - Food Frontiers
IS - 6
ER -
